Загрузка...
The End Point Is Just the Beginning
Clinical trials to support registration of new drugs are arduous, lengthy, and expensive. Diabetes treatment trials intended to seek indications for glycemic control are facilitated by the regulatory acceptance of glycosylated hemoglobin (A1C) as a validated intermediate efficacy end point. However,...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Diabetes Technology Society
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208893/ https://ncbi.nlm.nih.gov/pubmed/22027330 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|